Abstract Body

Kaposi’s Sarcoma Herpesvirus (KSHV/HHV-8) expresses several viral products during latency and lytic replication cycle that block innate immune responses. It is therefore of interest to study antiviral approaches that can tip the balance and help the host mount an effective immune response. Recently, we have described how 25-hydroxycholesterol (25HC), a derivative of cholesterol, can block KSHV de novo infection of primary endothelial cells (HUVEC) at a post-entry step and decreases expression of viral genes. We wanted to determine whether 25HC inhibits other gammaherpesviruses. More importantly, we aimed to study how 25HC exerts its antiviral effect.

To test the antiviral effect of 25HC against Epstein-Barr Virus (EBV), another oncogenic gammaherpesvirus (often co-infecting certain cancers with KSHV, e.g. PEL ), we performed de novo infection of primary B cells with 25HC treatment and measured apoptosis using flow cytometry. We also quantitated EBV viral transcript levels using RT-qPCR. To characterize the gene regulatory pathways triggered by 25HC, we performed RNA sequencing (RNA-Seq) of HUVEC treated with 25HC and de novo infected with KSHV. Validation was performed by RT-qPCR. Single and combinatorial siRNA knockdown of candidate target genes screened from RNA-Seq analysis were performed to identify which genes were required for the antiviral activity of 25HC.

We found that 25HC increased apoptosis in EBV-infected cells, decreasing the number of EBV-transformed lymphoblastoid cell lines (LCLs). 25HC downregulated an RNA Pol III-transcribed EBV transcript, but not an RNA Pol II EBV transcript. RNA-Seq showed global suppression of KSHV viral gene expression with treatment of 25HC. On the other hand, 25HC increased Type I interferon-stimulated genes (ISGs), including inflammatory cytokines and chemokines. Using single and combinatorial siRNA-mediated knockdown, we found that depletion of certain candidate genes resulted in recovery of viral gene expression, validating their contribution towards the antiviral effect of 25HC in KSHV.

25HC rendered EBV-infected B cells unable to form LCLs. RNA-Seq data showed induction of inflammatory cytokines due to 25HC treatment. Loss-of-function experiments confirmed their role in the antiviral activity of 25HC. Our studies aim to elucidate how we can augment these intrinsic antiviral responses to pave the way for developing therapeutic strategies for multiple viral infections.